EN PL
ORIGINAL PAPER
Serum and urinary calcium level in Latvian patients with sarcoidosis
 
More details
Hide details
 
Submission date: 2018-09-18
 
 
Final revision date: 2018-12-02
 
 
Acceptance date: 2018-12-03
 
 
Online publication date: 2018-12-23
 
 
Publication date: 2018-12-23
 
 
Reumatologia 2018;56(6):377-381
 
KEYWORDS
TOPICS
ABSTRACT
Objectives:
Sarcoidosis is a multisystem granulomatous disease of unknown etiology that in 90% of cases affects the lungs. Calcium metabolism testing can be useful in diagnostics. The aim of the study was to assess the correlation between calcium metabolism and sarcoidosis form of manifestation/demographic indicators.

Material and methods:
In a retrospective study medical records of all patients (n = 699) who had been hospitalized with suspected sarcoidosis in a specialized clinic of Riga Eastern Clinical University Hospital during the period from January 1st, 2013 until December 31st, 2014 were analyzed. Further analysis included only patients with histologically and/or clinically confirmed sarcoidosis (n = 281).

Results:
Patients’ average age at the time of diagnosis was 39 ±13 years. Elevated serum calcium was observed in 9.9% of cases. A statistically significant correlation was found between serum calcium and age (p < 0.01). There was an association between serum calcium and gender (p < 0.05) – levels were higher in men (2.43 mmol/l) than in women (2.40 mmol/l). Elevated calcium in 24-hour urine was observed in 22.7% of patients. The mean value was 232.3 mg/24 h, levels were higher in men (258.7 mg/24 h) than in women (202.3 mg/24 h), and the association with gender was statistically significant (p < 0.01).

Conclusions:
We can conclude that in Latvia sarcoidosis affects mostly young and middle-aged people. Both serum calcium and calcium in 24-hour urine are important parameters for sarcoidosis diagnostics. Hypercalcemia was found in 9.9% of patients, hypercalciuria in 22.7% of patients, and both were statistically significantly higher in men, regardless of age. Key words: sarcoidosis, hypercalcemia, serum calcium level.

REFERENCES (28)
1.
Saidenberg-Kermanac’h N, Semerano L, Nunes H, et al. Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients. Arthritis Res Ther 2014; 16: R78.
 
2.
Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet 2014; 383: 1155-1167.
 
3.
Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305: 391-399.
 
4.
Moller DR, Rybicki BA, Hamzeh NY, et al. Genetic, immunologic, and environmental basis of sarcoidosis. Ann Am Thorac Soc 2017; 14: S429-S436.
 
5.
Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357: 2153-2165.
 
6.
Kavathia D, Buckley JD, Rao D, et al. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med 2010; 104: 564-570.
 
7.
Birnie D, Ha AC, Gula LJ, et al. Cardiac sarcoidosis. Clin Chest Med 2015; 36: 657-668.
 
8.
Hewison, M. Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol 2010; 321: 103-111.
 
9.
Sodhi A, Aldrich T. Vitamin D supplementation: not so simple in sarcoidosis. Am J Med Sci 2016; 352: 252-257.
 
10.
Rizzato, G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax 1998; 53: 425-429.
 
11.
Holmes J, Lazarus A. Sarcoidosis: extrathoracic manifestations. Dis Mon 2009; 55: 675-692.
 
12.
Baughman RP, Lower EE. Goldilocks, vitamin D and sarcoidosis. Arthritis Res Ther 2014; 16: 111.
 
13.
United Nations, Statistics Division. Standard Country or Area Codes for Statistical Use (Rev. 4), Series M: Miscellaneous Statistical Papers, No. 49, New York: United Nations, ST/ESA/STAT/SER.M/49/Rev.4; 1999 (access: 9.09.2018). Available from: https://unstats.un.org/unsd/me....
 
14.
Tarcinska R, Baklasova A, Ruza I, et al. Calcium metabolism in Latvian patients with newly diagnosed sarcoidosis [poster session presentation]. 14th European Congress of Internal Medicine; 2015 Oct 14-16; Moscow, Russian Federation. Available from: https://www.efim2015.org/public/uploads/2015/EFIM/sessions/Posters%20Pulmonology-09-09.pdf.
 
15.
Lill H, Kliiman K, Altraja A. Factors signifying gender differences in clinical presentation of sarcoidosis among Estonian population. Clin Respir J 2016; 10: 282-290.
 
16.
Capolongo G, Xu LH, Accardo M, et al. Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis. J Investig Med 2016; 64: 1025-1034.
 
17.
Lim V, Clarke BL. Coexisting primary hyperparathyroidism and sarcoidosis cause increased angiotensin-converting enzyme and decreased parathyroid hormone and phosphate levels. J Clin Endocrinol Metab 2013; 98: 1939-1945.
 
18.
Kamphuis LS, Bonte-Mineur F, van Laar JA, et al. Calcium and vitamin D in sarcoidosis: is supplementation safe? J Bone Miner Res 2014; 29: 2498-2503.
 
19.
Bolland MJ, Wilsher ML, Grey A, et al. Randomised controlled trial of vitamin D supplementation in sarcoidosis. BMJ Open 2013; 3: e003562.
 
20.
Baughman RP, Papanikolaou I. Current concepts regarding calcium metabolism and bone health in sarcoidosis. Curr Opin Pulm Med 2017; 23: 476-481.
 
21.
Adler RA, Funkhouser HL, Petkov VI, et al. Glucocorticoid-induced osteoporosis in patients with sarcoidosis. Am J Med Sci 2003;325:1-6.
 
22.
Kling JM, Clarke BL, Sandhu NP. Osteoporosis prevention, screening, and treatment: a review. J Womens Health 2014; 23: 563-572.
 
23.
Lejnieks A, Slaidina A, Zvaigzne A, et al. Vitamin D status and its seasonal variations and association with parathyroid hormone concentration in healthy women in Riga. Medicina (Kaunas, Lithuania) 2013; 49: 329-334.
 
24.
Mukane M, Rasa I, Mukans M. First epidemiological study about vitamin D status and lifestyle factors in healthy young adults from Latvia Y: DLAT study (part I). Osteoporosis Int 2015; 26: P359.
 
25.
Sweiss NJ, Lower EE, Korsten P, et al. Bone health issues in sarcoidosis. Curr Rheumatol Rep 2011; 13: 265-272.
 
26.
Bucova M, Suchankova M, Tibenska E, et al. TREM-2 receptor expression increases with 25(OH)D vitamin serum levels in patients with pulmonary sarcoidosis. Mediators Inflamm 2015; 2015: 1-7.
 
27.
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee. Am J Respir Crit Care Med 1999; 160: 736-755.
 
28.
Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis 2018; 9: 227-240.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top